Venetoclax for AML: changing the treatment paradigm

Volume: 3, Issue: 24, Pages: 4326 - 4335
Published: Dec 23, 2019
Abstract
Venetoclax is a specific B-cell lymphoma-2 (BCL-2) inhibitor that can restore activation of apoptosis in malignancies, the survival of which depends on dysregulation of this pathway. Preclinical data, using various model systems including cell lines and patient samples, suggested targeting BCL-2 could be a successful therapeutic strategy in patients with acute myeloid leukemia (AML). As predicted by this work, the use of venetoclax in the...
Paper Details
Title
Venetoclax for AML: changing the treatment paradigm
Published Date
Dec 23, 2019
Volume
3
Issue
24
Pages
4326 - 4335
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.